Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 and SG001 with dCRT in Esophageal Squamous Carcinoma
NCT06136988Phase 2Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2023
- Primary completion
- Apr 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel, PBI-1308 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
albumin-bound docetaxelPBI-1308
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06136988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136988.